Most patients who test positive for the C. diff antigen (GDH) but negative for toxin do not need antibiotic treatment for Clostridioides difficile infection. This “discordant” result is one of the most common diagnostic gray zones in hospital medicine, and it usually means the organism is present in the gut without actively causing disease. European and North American guidelines both recommend clinical evaluation rather than automatic treatment for these patients, because a large share of them are colonized carriers, not infected. That said, certain clinical scenarios and patient populations flip the calculus, and a blanket “never treat” rule would miss genuinely sick people.
What a Positive Antigen With Negative Toxin Actually Tells You
The GDH (glutamate dehydrogenase) antigen test detects a protein produced by all strains of C. difficile, whether or not those strains make the toxins that cause colitis. A positive GDH result tells you the organism is in the stool. The toxin enzyme immunoassay (EIA) looks specifically for toxins A and B, which are the molecules that damage the intestinal lining and cause diarrhea, inflammation, and pseudomembranes. When the GDH is positive but the toxin EIA is negative, there are a few possibilities: the patient may be colonized with a toxin-producing strain that is not releasing enough toxin to be detected; they may carry a non-toxigenic strain that will never cause disease; or the toxin test may simply have missed a low concentration of toxin.
The toxin EIA is not a particularly sensitive test. In one study comparing multiple diagnostic methods against toxigenic culture, the toxin EIA alone had a sensitivity of only about 58%, meaning it missed roughly four out of ten true infections. PCR-based methods, by contrast, had sensitivity above 94%.1PubMed Central. Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms This gap is exactly why many hospitals use a two-step algorithm: GDH first as a screen, then a confirmatory test. European guidance explicitly states that no single commercial test works well enough on its own, and that GDH-positive, toxin-negative samples require clinical judgment to distinguish true infection from carriage.2Clinical Microbiology and Infection. European Society of Clinical Microbiology and Infectious Diseases: Update of the diagnostic guidance document for Clostridium difficile infection
The Evidence for Observation Over Immediate Treatment
Several studies have now directly examined what happens when you withhold antibiotics from patients with discordant results. The most substantial is a quasi-experimental study of 632 hospitalized adults with PCR-positive but toxin-negative results. Before the hospital changed its practice, about 92% of these patients received CDI treatment. After an intervention encouraging clinicians to withhold therapy, only about 15% were treated. The results were reassuring: rates of diarrhea resolution at seven days and 30-day mortality were similar between the two groups, and the study established noninferiority for both of those endpoints.3PubMed Central. Clinical Outcomes of Treated and Untreated C. difficile PCR-Positive/Toxin-Negative Adult Hospitalized Patients: a Quasi-Experimental Noninferiority Study The study did note that two outcomes, symptomatic toxin conversion at eight weeks and hospital length of stay, did not meet the predefined noninferiority thresholds, which means the question is not entirely settled.
Smaller studies reinforce the trend. One analysis of transplant patients (bone marrow and solid organ) found that 96% of those with PCR-positive but toxin-negative results who were observed rather than treated did not go on to develop CDI.4Open Forum Infectious Diseases. 677. To Treat or Not To Treat: Patients with Clostridioides difficile PCR-positive/Toxin EIA negative Test Results Another found that among 54 toxin-negative patients who went untreated, only three (about 6%) were later diagnosed with CDI, and none had complications.5PubMed Central. Clinical outcomes and treatment necessity in patients with toxin-negative Clostridioides difficile stool samples These numbers are consistent with the general understanding that most GDH-positive, toxin-negative patients are carriers rather than patients with active CDI.
In practice, many clinicians have already absorbed this message. One study at a large medical center found that about 59% of patients with toxin-negative but PCR-positive results received no treatment at all, while another 28% received only a partial course of antibiotics.6PubMed Central. Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era The most common reason clinicians gave for treating despite discordant results was high clinical suspicion that the patient truly had CDI, regardless of what the toxin test said.7Antimicrobial Stewardship & Healthcare Epidemiology. Clinician Interpretation and Management of Discordant PCR+/Toxin- Clostridioides difficile Testing Results Post-COVID
When Negative Toxin Does Not Mean Safe to Watch and Wait
The recommendation to observe rather than treat applies to patients who lack clinical features of CDI, and the emphasis matters. If someone has a GDH-positive, toxin-negative result but their clinical picture screams C. diff, such as new-onset watery diarrhea with abdominal pain, fever, a rising white blood cell count, or signs of colitis on imaging, many infectious disease specialists will treat empirically regardless of the toxin result. The reasoning is straightforward: the toxin EIA misses a lot of real infections, and you do not want to sit on your hands while a patient deteriorates because of a test with 58% sensitivity.
One published case report describes a patient who developed toxic megacolon, one of the most dangerous complications of CDI, despite having a positive C. difficile antigen but a negative toxin assay. The authors frame it as a well-documented but dangerously overlooked phenomenon: test sensitivity fails precisely in the sickest patients.8PubMed Central. Toxic Megacolon With a Positive Clostridioides difficile Antigen but Negative Toxin Assay This is the worst-case scenario of taking a negative toxin result at face value without weighing the clinical picture.
Guideline recommendations from both IDSA-SHEA and ESCMID emphasize this point: discordant results without clinical features of CDI should generally not prompt treatment, to minimize unnecessary antibiotic exposure.9Infection Control & Hospital Epidemiology. Patients with Positive Glutamine Dehydrogenase (GDH) Antigen/Toxin and Toxin Negative/PCR Positive Patients: A Comparison The flip side, though, is that discordant results with clinical features of CDI do warrant treatment. The test result does not override the bedside assessment.
Immunocompromised Patients Are a Different Story
The “observe and wait” approach is least reliable in patients with weakened immune systems. A study of immunocompromised patients found that several factors independently predicted a false-negative toxin EIA: high-dose corticosteroid use roughly tripled the odds of a negative toxin test despite a positive toxigenic culture, and severe leukocytopenia (very low white blood cell counts) more than doubled the odds. The authors concluded that a negative toxin EIA simply does not rule out CDI in immunocompromised patients who have relevant symptoms.10PubMed. Low sensitivity of fecal toxin A/B enzyme immunoassay for diagnosis of Clostridium difficile infection in immunocompromised patients
This finding makes biological sense. The immune response to C. difficile toxins contributes to the inflammatory diarrhea that characterizes CDI. Patients on immunosuppressive therapy may mount a weaker inflammatory response, which could result in lower concentrations of free toxin in stool, below the detection threshold of the EIA. In these patients, a more sensitive method like PCR or toxigenic culture is a better confirmatory step. If only a GDH/toxin two-step result is available and the toxin is negative, clinicians caring for transplant recipients, patients on high-dose steroids, or those with hematologic malignancies should have a lower threshold to treat empirically.
Asymptomatic Colonization and Why Testing Matters
One underappreciated fact is that a substantial number of hospitalized patients carry C. difficile in their gut without any symptoms. Among asymptomatic colonized patients, more than half carry toxigenic strains, the kind capable of producing toxins and potentially causing disease.11PubMed Central. Asymptomatic Clostridium difficile colonization: epidemiology and clinical implications These people will test GDH-positive and may even be PCR-positive, but they are not sick, and treating them with antibiotics would be harmful rather than helpful. Antibiotics disrupt the gut flora that is actually keeping the C. difficile in check.
This is why diagnostic stewardship, the practice of controlling when tests are ordered in the first place, has become central to C. difficile management. The 2017 IDSA-SHEA guidelines recommend different diagnostic strategies depending on whether an institution has implemented policies to ensure that only patients with genuine, clinically significant diarrhea get tested.12De Gruyter / Diagnosis. Diagnostic stewardship and the 2017 update of the IDSA-SHEA Clinical Practice Guidelines for Clostridium difficile Infection If a hospital’s ordering practices are loose, and stool samples are being sent on patients with formed stool or diarrhea from laxatives or tube feeds, the false-positive rate for colonization goes up, and the GDH-positive, toxin-negative result becomes even less meaningful. One study found that laxative use did not preclude a valid CDI diagnosis or reduce disease severity, but the broader point stands: the test result is only as useful as the clinical question behind it.13PubMed Central. Laxative Use Does Not Preclude Diagnosis or Reduce Disease Severity in Clostridiodes difficile Infection
Should You Repeat the Test?
A common instinct when the toxin comes back negative is to send another sample. The evidence on repeat testing is not encouraging. One large study of repeat enzyme immunoassay testing found that among initially negative tests, only about 1.8% were positive when repeated the next day, and only 3.8% on day two. None of the patients who converted within 48 hours had medical complications. The authors concluded that repeating C. difficile testing within two days of a negative result adds little diagnostic value.14PubMed Central. Evaluation of repeat Clostridium difficile enzyme immunoassay testing A separate study found that repeat sampling picked up only about 5 to 9% additional positives across both epidemic and non-epidemic settings, and most of these came from later rounds of testing rather than immediate repeats.15PubMed Central. Diagnostic yield of repeat sampling with immunoassay, real-time PCR, and toxigenic culture for the detection of toxigenic Clostridium difficile in an epidemic and a non-epidemic setting
If you are going to repeat anything, waiting at least a week is more productive than sending another sample the same day. And if clinical suspicion is high enough to warrant repeat testing, it may be more useful to escalate the test method (to PCR or toxigenic culture) rather than repeating the same toxin EIA that already came back negative.
Other Causes of Diarrhea Worth Considering
When the GDH is positive but the toxin is negative and the patient has diarrhea, it is worth remembering that C. difficile may not be the culprit at all. The patient could be colonized with C. difficile while their diarrhea is actually caused by something else entirely. One study tested stool samples from patients with negative C. difficile results and found alternative infectious causes, including norovirus, rotavirus, enteropathogenic E. coli, and Salmonella, in about 13% of specimens. For most patients, no infectious cause was identified, but the majority had disrupted gut microbiota that could itself contribute to loose stools.16PubMed Central. Alternative Causes of Infectious Diarrhea in Patients with Negative Tests for Clostridoides Difficile In a hospitalized patient receiving antibiotics and tube feeds, the differential diagnosis for diarrhea is broad, and reflexively attributing it to C. difficile because the GDH lit up can lead to overtreatment.
Where Diagnostics Are Headed
The fundamental problem with the current two-step approach is that GDH is too sensitive (it catches carriers) and toxin EIA is not sensitive enough (it misses real infections). Researchers are working on ultrasensitive toxin assays that can detect toxin at concentrations far below what conventional EIA picks up, potentially closing the gap that creates so many discordant results in the first place.
One approach uses single-molecule array (Simoa) technology, which can detect C. difficile toxin A at concentrations as low as 0.6 picograms per milliliter and toxin B at 2.9 picograms per milliliter, far below what standard EIA tests require.17PubMed Central. Sensitivity of Single-Molecule Array Assays for Detection of Clostridium difficile Toxins in Comparison to Conventional Laboratory Testing Algorithms Another ultrasensitive assay, the Singulex Clarity C. diff toxins A/B test, uses a cutoff of 12 picograms per milliliter and showed strong agreement with cell culture cytotoxicity testing once discrepant samples were resolved, reaching above 96% positive agreement and 93% negative agreement.18PubMed Central. Ultrasensitive Detection of Clostridioides difficile Toxins in Stool by Use of Single-Molecule Counting Technology: Comparison with Detection of Free Toxin by Cell Culture Cytotoxicity Neutralization Assay
In theory, these ultrasensitive assays could function as standalone tests, eliminating the need for a two-step algorithm and the discordant results that follow from it. In practice, large clinical validation studies are still needed before they replace current workflows.19PubMed Central. Ultrasensitive Clostridioides difficile Toxin Testing for Higher Diagnostic Accuracy For now, they represent the most promising path toward resolving the GDH-positive, toxin-negative dilemma at the laboratory level rather than leaving it to bedside guesswork.
The Cost of Getting It Wrong in Either Direction
The clinical stakes of this question run both ways. Treat a colonized patient who does not have CDI and you expose them to unnecessary antibiotics, which ironically increases their future risk of developing CDI by further disrupting their gut flora. You also contribute to antibiotic resistance and drive up costs. An economic analysis estimated that for every 10,000 symptomatic adults tested, a GDH-based screening algorithm identified about 831 true-positive cases at a cost of roughly $1,600 per additional correctly treated case, while stand-alone PCR was more effective but more expensive at about $6,900 per additional case.20PubMed Central. Economic evaluation of laboratory testing strategies for hospital-associated Clostridium difficile infection Neither strategy is perfect, and every testing approach involves tradeoffs between sensitivity, specificity, and cost.
Miss a true infection in the other direction, and you risk complications including prolonged illness, colectomy, or death. This is especially true for the subset of patients who have severe CDI with falsely negative toxin assays, the population described in the toxic megacolon case report. The balance point for most clinicians is to observe low-risk patients with discordant results, while treating those whose clinical picture is convincing for CDI regardless of what the toxin test says. Neither reflexive treatment nor reflexive dismissal serves patients well.